Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, highlighting significant progress in its pipeline of non-opioid pain and neuropathy treatments. The company, based in Alpharetta, GA, is developing first-in-class medicines targeting pain and neuropathic disorders.
CEO Greg Duncan noted a strong operational start to 2026, driven by pipeline advancements for both Halneuron® and SP16. The company has enrolled 164 patients in its Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP), with top-line results anticipated in fall 2026. Halneuron® is a non-opioid NaV 1.7 inhibitor that has received fast track designation from the FDA for CINP.
Additionally, SP16, a low-density lipoprotein receptor related protein-1 agonist, received IND approval from the FDA for a Phase 1b trial targeting chemotherapy-induced pain and peripheral neuropathy (CIPPN). This study, fully funded by the National Cancer Institute, will be conducted at the University of Virginia and is set to begin enrollment in mid-2026. SP16 has shown preclinical anti-inflammatory and tissue-repair potential.
In January 2026, the company completed a financing of up to $26.9 million, with $12.5 million in gross proceeds received, to advance Halneuron® through Phase 2b. As of March 31, 2026, Dogwood held $13.2 million in cash, providing operational runway into the fourth quarter of 2026.
First quarter financial results revealed research and development expenses of $2.7 million, up from $2.4 million in the same period of 2025, driven by increased drug development costs for Halneuron® and higher personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to increased salaries and personnel costs. Net loss attributable to common stockholders narrowed to $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the first quarter of 2025.
The company also executed a global development license for its legacy combination antiviral assets, though specific terms were not disclosed. Dogwood's largest shareholder is a member of CK Life Sciences Int’l., (Holdings) Inc., listed on the Hong Kong Stock Exchange.
These developments underscore Dogwood's commitment to addressing the unmet need for non-opioid pain treatments, particularly for chemotherapy-induced neuropathy, a debilitating condition affecting many cancer patients. The upcoming data readouts and trial initiations represent potential milestones for the company and the broader pain management landscape.
